Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
LEXINGTON, Mass., Oct. 27, 2016 -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that the Company will release its third quarter 2016 financial results on Thursday, November 3, 2016, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EDT.
To access the live conference call, please dial (877) 868-1829 from the United States or (253) 237-1135 from other locations, shortly before 8:30 a.m. EDT. The conference ID number is 6507701. The conference call can also be accessed on the Curis website at www.curis.com in the Investors section.
About Curis, Inc.
Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907 that is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD-1 and VISTA pathways, including PD-L1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD-1 and TIM-3 pathways, including PD-L1/TIM-3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in other diseases including idiopathic pulmonary fibrosis and myelofibrosis. For more information, visit Curis' website at www.curis.com.
For More Information: James E. Dentzer Chief Financial Officer & Chief Administrative Officer Curis, Inc. 617-503-6500 [email protected] Media Contact: David Schull Russo Partners 212-845-4271 [email protected]
